Neurocrine Biosciences
NBIX
225 hedge funds and large institutions have $3.27B invested in Neurocrine Biosciences in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 97 increasing their positions, 75 reducing their positions, and 41 closing their positions.
97.13% more ownership
Funds ownership: 0% → 97.13% (+97%)
29% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 75
6% less call options, than puts
Call options by funds: $23.6M | Put options by funds: $25.1M
8% less funds holding
Funds holding: 244 → 225 (-19)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
24% less capital invested
Capital invested by funds: $4.32B → $3.27B (-$1.05B)
37% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 41
Top Buyers
| 1 |
Millennium Management
New York
|
+$55.6M |
| 2 |
HM
HealthCor Management
New York
|
+$44.8M |
| 3 |
PA
Perceptive Advisors
New York
|
+$38M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$18M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$16.1M |
Top Sellers
NBIX Hedge Fund Activity: Q4 2016 in Review
225 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2016, worth a combined $3.27B — down 24% from $4.32B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of NBIX and 26 opened new positions — a net loss of 15 holders — while 75 trimmed existing stakes and 97 added.
The largest buyer was Millennium Management, adding an estimated $55.6M. The largest seller was T. Rowe Price Associates, cutting an estimated $153M.
- 225 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2016, down from 244 in Q3 2016.
- Funds reported $3.27B of Neurocrine Biosciences stock for Q4 2016, down 24% quarter-over-quarter.
- 26 funds opened new Neurocrine Biosciences positions in Q4 2016 and 41 closed out, a net change of -15 holders.
- The largest Neurocrine Biosciences buyer in Q4 2016 was Millennium Management, an estimated $55.6M added.
- The largest Neurocrine Biosciences seller in Q4 2016 was T. Rowe Price Associates, an estimated $153M sold.
Based on aggregated 13F filings for Q4 2016.